Neurocrine Biosciences is writing a $2.9 billion check for Soleno Therapeutics — $53 per share in cash.
What Neurocrine is actually buying: Vykat XR, Soleno’s approved treatment for Prader-Willi syndrome. Prader-Willi is a rare genetic disorder that causes unrelenting hunger. There’s no cure, no crowded field, and until Vykat XR, no approved drug targeting the metabolic core of the disease. Soleno isn’t a pipeline story — it’s a commercial-stage asset with real revenue.
Neurocrine isn’t buying a bet. It’s buying a launched, profitable rare disease franchise and folding it into a specialty neuroscience portfolio that already includes Ingrezza for tardive dyskinesia. The strategic logic is clean: rare CNS diseases, existing commercial infrastructure, limited competition. The premium is aggressive but not insane for a profitable rare disease asset in this market.
The number that matters isn’t the $2.9B headline — it’s the revenue multiple Neurocrine is paying. Soleno’s profitability suggests Vykat XR has found its patient base, which means Neurocrine is paying for durability, not hope. Compare this to the typical rare disease acquisition where the acquirer is really just buying an FDA approval and crossing their fingers on commercial execution. Soleno already did that part.
The deal closes subject to customary regulatory and shareholder approvals. Worth watching whether Neurocrine’s Q2 guidance gets revised upward to reflect Vykat XR’s contribution.
— Diana Kowalski